Although YAP1 and TAZ are equivalently placed as downstream effectors of the Hippo pathway with oncogenic roles in human cancers, several lines of evidence indicate that YAP1 and TAZ are not functionally reductant and exert distinct functions depending on the cancer types involved [16, 20–23]. This evidence concerns the gene YAP1 and cancer.